CD34 and autoimmune thrombocytopenic purpura: ATRA partially corrects the impairment of MSCs in ITP patients and partially restores the ability of MSCs in ITP patients and healthy controls to induce CD34+-derived regDCs, which is therapeutic for ITP (Xu et al., 2017).